ResMed (NYSE: RMD) reported Q3 EPS of $1.32, $0.10 worse than the analyst estimate of $1.42. Revenue for the quarter came in at $864.5 million versus the consensus estimate of $897.04 million.

For earnings history and earnings-related data on ResMed (RMD) click here.